Prolight Diagnostics AB (publ) publishes annual report for 2025
Prolight Diagnostics AB (publ) has today published its Annual Report for the financial year 2025. The report is available via the attached file or on the Company’s website: https://prolightdx.com/en/investors/financial-reports/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, […]
Prolight Diagnostics achieves design freeze for Psyros® instrument
Prolight Diagnostics today announces that it has achieved formal design freeze of the instrument for the Psyros platform, a key milestone toward clinical development and scalable manufacturing. “Achieving instrument design freeze is a large and decisive step forward. The final design supports scalable manufacturing and reliable performance in demanding clinical environments such as ambulances and […]
Prolight secures second patent in Japan for Psyros® technology
Prolight Diagnostics announces today that the Japan Patent Office, JPO has issued an official Decision to Grant notification for a second patent application relating to the Psyros single-molecule-counting technology. The official legal notification was dated the 24th of April 2026. “Securing a second patent in Japan represents an important milestone and further strengthens our intellectual property position in a strategically important market. The patent demonstrates the […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Tuesday 26 May 2026 at 1 p.m. at the NGM’s (Nordic Growth Market) office, Stureplan 2, 114 35 Stockholm, Sweden. Notification of attendance Shareholders who wish to participate in the annual […]
Prolight selected as semi-finalist for ADLM 2026 Disruptive Technology Award Competition
Prolight Diagnostics, pioneer of point-of-care technology, today announces that they have been selected as a semi-finalist for the prestigious Disruptive Technology Award Competition (DTAC) organized by the Association for Diagnostics and Laboratory Medicine (ADLM). As a DTAC semi-finalist, Prolight are guaranteed exhibition space in the Disruptive Technology area at the ADLM annual meeting in Anaheim, California, July 26th-30th 2026. The six semi-finalists will present their technologies to the DTAC committee […]
Prolight Diagnostics publishes investorletter for March 2026
The investor letter highlights that Prolight has entered the year with several important milestones that further strengthen the position of our POC platform, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury […]
Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform
Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros unique single-molecule-counting platform and reinforcing its potential to […]
Prolight Diagnostics’ POC system Psyros attracted significant attention at the recently concluded international WHX Labs congress
According to an article published by BioStock, the Psyros system generated strong interest at the global WHX Labs industry exhibition in Dubai, where it was showcased by the contract manufacturer FlexMedical Solutions. Read the full article here: https://biostock.se/en/2026/03/stort-intresse-for-prolights-poc-system-i-takt-med-att-tillverkningspartnern-vaxlar-upp/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight […]
Biostock publishes an article after Prolight published its Year-End Report for 2025
Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026, Prolight is firmly setting its sights on a commercial launch in 2027. Read the full article here: https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 […]
Prolight Diagnostics publishes year-end report 2025
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, 2025 Net sales amounted to 0 (0). Other operating income amounted to 10,670 (15,317) TSEK. Operating profit (EBIT) amounted to -13,060 (1,492) TSEK Profit after tax amounted to -12,123 (2,014) TSEK. Earnings per share before […]